154 related articles for article (PubMed ID: 24219296)
1. Recombinant human PDCD5 protein enhances chemosensitivity of breast cancer in vitro and in vivo.
Wang L; Wang C; Su B; Song Q; Zhang Y; Luo Y; Li Q; Tan W; Ma D; Wang L
Biochem Cell Biol; 2013 Dec; 91(6):526-31. PubMed ID: 24219296
[TBL] [Abstract][Full Text] [Related]
2. Potent antitumor activities of recombinant human PDCD5 protein in combination with chemotherapy drugs in K562 cells.
Shi L; Song Q; Zhang Y; Lou Y; Wang Y; Tian L; Zheng Y; Ma D; Ke X; Wang Y
Biochem Biophys Res Commun; 2010 May; 396(2):224-30. PubMed ID: 20398626
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo.
Chen C; Zhou H; Xu L; Xu D; Wang Y; Zhang Y; Liu X; Liu Z; Ma D; Ma Q; Chen Y
Apoptosis; 2010 Jul; 15(7):805-13. PubMed ID: 20349137
[TBL] [Abstract][Full Text] [Related]
4. ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel.
Mao J; Song B; Shi Y; Wang B; Fan S; Yu X; Tang J; Li L
Int J Biochem Cell Biol; 2013 Jun; 45(6):1064-73. PubMed ID: 23500524
[TBL] [Abstract][Full Text] [Related]
5. Transfection of PDCD5 sensitizes colorectal cancer cells to cisplatin-induced apoptosis in vitro and in vivo.
Yin A; Jiang Y; Zhang X; Zhao J; Luo H
Eur J Pharmacol; 2010 Dec; 649(1-3):120-6. PubMed ID: 20869960
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
Chang J; Sui M; Fan W
Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
[TBL] [Abstract][Full Text] [Related]
9. [Sensitizing effect of recombinant human PDCD5 protein on chemotherapy of acute monocytic leukemia cell line U937 and its mechanism].
Wang YF; Song QS; Zhang YM; Ma DL; Wang Y; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):277-81. PubMed ID: 20416151
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human PDCD5 exhibits an antitumor role in hepatocellular carcinoma cells via clathrin‑dependent endocytosis.
Fu DZ; Cheng Y; He H; Liu HY; Liu YF
Mol Med Rep; 2015 Dec; 12(6):8135-40. PubMed ID: 26498344
[TBL] [Abstract][Full Text] [Related]
11. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model.
Kang HJ; Lee SH; Price JE; Kim LS
Breast J; 2009; 15(3):223-9. PubMed ID: 19645775
[TBL] [Abstract][Full Text] [Related]
12. An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer.
Zeng WG; Li JJ; Hu P; Lei L; Wang JN; Liu RB
Oncol Rep; 2013 Jun; 29(6):2355-61. PubMed ID: 23525624
[TBL] [Abstract][Full Text] [Related]
13. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
[TBL] [Abstract][Full Text] [Related]
14. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment.
Zhou Y; Inaba S; Liu J
Int J Oncol; 2006 Jul; 29(1):289-95. PubMed ID: 16773211
[TBL] [Abstract][Full Text] [Related]
16. Anticancer activity of litchi fruit pericarp extract against human breast cancer in vitro and in vivo.
Wang X; Yuan S; Wang J; Lin P; Liu G; Lu Y; Zhang J; Wang W; Wei Y
Toxicol Appl Pharmacol; 2006 Sep; 215(2):168-78. PubMed ID: 16563451
[TBL] [Abstract][Full Text] [Related]
17. A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines.
Xie M; Niu JH; Chang Y; Qian QJ; Wu HP; Li LF; Zhang Y; Li JL; Huang XJ; Ruan GR
Apoptosis; 2009 Sep; 14(9):1086-94. PubMed ID: 19551515
[TBL] [Abstract][Full Text] [Related]
18. The roles of serum PDCD5 in circulating CD133 positive cells of the patients with gastric cancer.
Wang D; Wang W; Song CL; Xia P
Tumour Biol; 2016 Sep; 37(9):11799-11804. PubMed ID: 27034262
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death.
Sui M; Huang Y; Park BH; Davidson NE; Fan W
Cancer Res; 2007 Jun; 67(11):5337-44. PubMed ID: 17545614
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]